Prevent Cardiac Surgery Associated AKI Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 242 participants.

Also called NCT06620523

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 242 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06620523
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06620523. Randomized; triple masking; primary purpose treatment. Start 2024-07-18 (actual); primary completion 2027-06-17 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prevent Cardiac Surgery Associated AKI Trial
Condition
Renal Failure
Condition
Surgery
Condition
Surgery-Complications
Intervention (Drug)
CoQ10 1200 mg orally with Glutathione 1000 mg orally
Intervention (Drug)
Group B: Placebo CoQ10 orally and Placebo Glutathione orally
Lead sponsor
George Washington University (class: other)

Record details

Record id
cardio:ct-nct06620523
Content hash
f54624f96bcf8922b895509d2a4d18e89028684c493788a10464f9983c4a4a12